🇺🇸 FDA
Pipeline program

Anti-HER2 CAR-T cells

Anti-HER2 CAR-T

Unknown mab active

Quick answer

Anti-HER2 CAR-T cells for HER2-positive Advanced Malignant Solid Tumors is a Unknown program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
HER2-positive Advanced Malignant Solid Tumors
Phase
Unknown
Modality
mab
Status
active

Clinical trials